United Therapeutics (UTHR) Misses Q2 EPS by 63c
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $487.61 -0.54%
Revenue Growth %: -1.2%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -1.2%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $5.85, $0.63 worse than the analyst estimate of $6.48. Revenue for the quarter came in at $714.9 million versus the consensus estimate of $689.93 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- JPMorgan Reiterates Overweight Rating on Legrand SA (LR:FP) (LGRDY) and Places on Positive Catalyst Watch
- JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
